Pancreatic cancer: pathogenesis, prevention and treatment.

Pancreatic cancer is the fourth leading cause of cancer death in the United States with a very low survival rate of 5 years. To better design new preventive and/or therapeutic strategies for the fight against pancreatic cancer, the knowledge of the pathogenesis of pancreatic cancer at the molecular level is very important. It has been known that the development and the progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways among which the EGFR, Akt, and NF-kappaB pathways appear to be most relevant. Therefore, the strategies targeting EGFR, Akt, NF-kappaB, and their downstream signaling could be promising for the prevention and/or treatment of pancreatic cancer. In this brief review, we will summarize the current knowledge regarding the pathogenesis, prevention, and treatment of pancreatic cancer.

[1]  R. Woutersen,et al.  Modulation of pancreatic carcinogenesis by antioxidants. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[2]  C P Neal,et al.  Molecular prognostic markers in pancreatic cancer: a systematic review. , 2005, European journal of cancer.

[3]  Douglas B. Evans,et al.  Function of Nuclear Factor κB in Pancreatic Cancer Metastasis , 2003 .

[4]  A. Tamakoshi,et al.  Nutritional factors and risk of pancreatic cancer: a population-based case-control study based on direct interview in Japan , 2005, Journal of Gastroenterology.

[5]  N. Lemoine,et al.  Gene therapy developments for pancreatic cancer. , 2006, Best practice & research. Clinical gastroenterology.

[6]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[7]  Ming-Sound Tsao,et al.  A review of erlotinib and its clinical use , 2006, Expert opinion on pharmacotherapy.

[8]  G. Firestone,et al.  Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. , 1999, Cancer research.

[9]  J. Abbruzzese,et al.  Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity , 2004, Cancer Research.

[10]  M. Mimeault,et al.  Recent Advances on the Molecular Mechanisms Involved in Pancreatic Cancer Progression and Therapies , 2005, Pancreas.

[11]  Zhiwei Wang,et al.  Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells , 2006, Molecular Cancer Therapeutics.

[12]  Masafumi Nakamura,et al.  Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. , 2006, Cancer research.

[13]  S. Cosimo,et al.  Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma , 2004, Cancer.

[14]  H. Heng,et al.  Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene–Expressing Pancreatic Tumor Cell Line , 2005, Clinical Cancer Research.

[15]  R. Hruban,et al.  Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. , 2003, Cancer cell.

[16]  Zhiwei Wang,et al.  Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. , 2006, Cancer research.

[17]  Douglas B. Evans,et al.  Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA , 1999, Oncogene.

[18]  Shadan Ali,et al.  Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. , 2004, Molecular cancer therapeutics.

[19]  H. Zhang,et al.  PSK-mediated NF-κB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1 , 2003, Oncogene.

[20]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[21]  T. Yano,et al.  Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. , 2003, Research communications in molecular pathology and pharmacology.

[22]  Zhiwei Wang,et al.  Retracted: Inhibition of nuclear factor κb activity by genistein is mediated via Notch‐1 signaling pathway in pancreatic cancer cells , 2006, International journal of cancer.

[23]  H. Kalthoff,et al.  Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer , 2003, International journal of cancer.

[24]  F. Kadlubar,et al.  Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. , 1999, Nutrition and cancer.

[25]  K. Matsumoto,et al.  Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival , 2006, Cancer Gene Therapy.

[26]  T. Adrian,et al.  Resveratrol Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells , 2002, Pancreas.

[27]  Zhiwei Wang,et al.  Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. , 2005, Cancer research.

[28]  Sanjeev Banerjee,et al.  Retracted: Cisplatin‐induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC‐3 pancreatic tumor xenografts , 2006, Cancer.

[29]  V. Adhami,et al.  Green tea constituent epigallocatechin‐3‐gallate selectively inhibits COX‐2 without affecting COX‐1 expression in human prostate carcinoma cells , 2005, International journal of cancer.

[30]  Zhiwei Wang,et al.  Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. , 2006, Cancer research.

[31]  L. Pradayrol,et al.  Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  D B Evans,et al.  Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  F. Sarkar,et al.  Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. , 2005, Cancer research.

[34]  R. Hruban,et al.  Molecular pathogenesis of pancreatic cancer. , 2006, Annual review of genomics and human genetics.

[35]  W. Willett,et al.  Vitamin D Intake and the Risk for Pancreatic Cancer in Two Cohort Studies , 2006, Cancer Epidemiology Biomarkers & Prevention.

[36]  D. Iannitti,et al.  Erlotinib and Chemoradiation Followed by Maintenance Erlotinib for Locally Advanced Pancreatic Cancer: A Phase I Study , 2005, American Journal of Clinical Oncology.

[37]  R. Wolff,et al.  Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Hedley,et al.  Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. , 2005, Cancer research.

[39]  M. Korc,et al.  Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. , 1998, The Journal of clinical investigation.

[40]  Zhiwei Wang,et al.  Retracted: Notch‐1 down‐regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells , 2006, Cancer.

[41]  Mohammad Saleem,et al.  Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. , 2006, Cancer research.

[42]  C. Yashar,et al.  Potentiation of the radiation effect with genistein in cervical cancer cells. , 2005, Gynecologic oncology.

[43]  H. Friess,et al.  The Notch Signaling Pathway Is Related to Neurovascular Progression of Pancreatic Cancer , 2005, Annals of surgery.

[44]  Shadan Ali,et al.  Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. , 2005, Cancer research.

[45]  P. Muscarella,et al.  The genetics of pancreatic cancer. , 2003, American journal of surgery.

[46]  J. Marshall.  Clinical implications of the mechanism of epidermal growth factor receptor inhibitors , 2006, Cancer.

[47]  Shadan Ali,et al.  Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-κB in BxPC-3 Pancreatic Cancer Cell Line , 2004, Pancreas.

[48]  R. Agarwal,et al.  Green tea in chemoprevention of cancer. , 1992, Comprehensive therapy.

[49]  Zhiwei Wang,et al.  Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. , 2005, Cancer research.

[50]  D. Karunagaran,et al.  Sensitization of Taxol-induced Apoptosis by Curcumin Involves Down-regulation of Nuclear Factor-κB and the Serine/Threonine Kinase Akt and Is Independent of Tubulin Polymerization* , 2005, Journal of Biological Chemistry.

[51]  Gregory Y. Lauwers,et al.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.

[52]  M. Abdelrahim,et al.  3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. , 2006, Carcinogenesis.

[53]  Yutaka Shimada,et al.  Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours , 2003, Nature.

[54]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[55]  M. Monden,et al.  Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Yiwei Li,et al.  Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. , 2006, Cancer research.

[57]  B. Aggarwal,et al.  Nuclear factor‐κB and IκB kinase are constitutively active in human pancreatic cells, and their down‐regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis , 2004, Cancer.

[59]  E. Małecka-Panas,et al.  Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[60]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[61]  S. Haldar,et al.  Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. , 2005, Carcinogenesis.

[62]  R. Bold,et al.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. , 2004, Journal of the American College of Surgeons.

[63]  C. Moskaluk,et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.

[64]  Yiwei Li,et al.  Indole-3-carbinol and prostate cancer. , 2004, The Journal of nutrition.

[65]  A. Jimeno,et al.  Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[66]  Zhiwei Wang,et al.  Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. , 2006, Cancer research.

[67]  D. Krewski,et al.  Dietary intake of lycopene is associated with reduced pancreatic cancer risk. , 2005, The Journal of nutrition.

[68]  Yiwei Li,et al.  Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. , 2005, Frontiers in bioscience : a journal and virtual library.

[69]  Molecular Analysis of the p53 Gene in Pancreatic Adenocarcinoma , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[70]  B. Lyn‐Cook,et al.  Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. , 2004, Anticancer research.

[71]  R. Schmid,et al.  Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancer , 2003, International journal of cancer.